DNAAF1: A Protein Involved in T Cell Development and Function

Target Name: DNAAF1

NCBI ID: G123872

DNAAF1

DNAAF1: A Protein Involved in T Cell Development and Function

DNAAF1 (doublecortin-alpha-1) is a protein that is expressed in various tissues of the body, including the brain, pancreas, and heart. It is a member of the superfamily of proteins known as the T-cell factor receptor (TCR) family, and it has been shown to play a role in the regulation of immune responses and inflammation.

One of the most interesting aspects of DNAAF1 is its potential as a drug target. The ability of DNAAF1 to interact with various signaling pathways, including the TCR signaling pathway, has led to its potential as a target for small molecules. Additionally, its expression in multiple tissues makes it a promising biomarker for a variety of diseases.

DNAAF1 has been shown to play a role in the regulation of T cell development and function. T cells are a type of immune cell that play a critical role in the regulation of the immune system, and DNAAF1 has been shown to be involved in this process.

One of the ways that DNAAF1 contributes to T cell development is through its role in the regulation of the cytoskeleton. The cytoskeleton is the structure that gives cells shape and stability, and it is essential for the proper functioning of many cellular processes. DNAAF1 has been shown to play a role in the regulation of the cytoskeleton by interacting with microtubules, which are the protein structures that give cells their shape.

In addition to its role in T cell development, DNAAF1 has also been shown to contribute to the regulation of T cell function. T cells are responsible for recognizing and responding to foreign antigens, and DNAAF1 has been shown to be involved in this process. It has been shown that DNAAF1 interacts with the protein PD-L1, which is a negative regulator of the immune response. This interaction between DNAAF1 and PD-L1 has been shown to play a role in the regulation of T cell responses to both foreign antigens and cancer cells.

DNAAF1 has also been shown to be involved in the regulation of inflammation. Chronic inflammation can have serious consequences for the health of the body, and DNAAF1 has been shown to be involved in the regulation of the immune response in the regulation of inflammation.

In addition to its role in T cell development and function, DNAAF1 has also been shown to be involved in the regulation of cell survival. DNAAF1 has been shown to interact with the protein p53, which is a protein that plays a critical role in the regulation of DNA damage and cell survival. This interaction between DNAAF1 and p53 has been shown to play a role in the regulation of cell survival and the prevention of apoptosis.

DNAAF1 has also been shown to be involved in the regulation of cellular signaling pathways. DNAAF1 has been shown to interact with the protein STAT3, which is a protein that plays a critical role in the regulation of inflammation and cellular signaling pathways. This interaction between DNAAF1 and STAT3 has been shown to play a role in the regulation of inflammation and cellular signaling pathways.

In conclusion, DNAAF1 is a protein that has been shown to play a role in the regulation of T cell development and function, inflammation, and cell survival. Its potential as a drug target makes it an attractive target for small molecules, and further research is needed to fully understand its role in the regulation of the immune system.

Protein Name: Dynein Axonemal Assembly Factor 1

Functions: Cilium-specific protein required for the stability of the ciliary architecture. Plays a role in cytoplasmic preassembly of dynein arms. Involved in regulation of microtubule-based cilia and actin-based brush border microvilli

The "DNAAF1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about DNAAF1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets